Brad Margus, chief executive of drug-discovery company Cerevance, said that lowering drug prices will especially hurt companies working on the hardest-to-crack diseases, where even though a drug that works would have a huge market, it’s nearly impossible to persuade investors to support new approaches. “The price controls now being pushed threaten to remove the chance for my investors to get those returns,” he said.